Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Unusual marker expression in acute leukaemia is associated with low remission rate (CROSBI ID 470965)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | domaća recenzija

Mrsić, Mirando ; Batinić, Drago ; Mrsić, Sanja ; Boban, Dubravka ; Nemet, Damir ; Užarević, Branka ; Bogdanić, Vinko ; Aurer, Igor ; Radman, Ivo ; Marković-Glamočak, Mirjana et al. Unusual marker expression in acute leukaemia is associated with low remission rate // V. seminar New Trends in the Treatment of Acute Leukemia / Mrsić, Mirando ; Labar, Boris (ur.). Zagreb: University Hospital Rebro Zagreb and European School of Oncology, 1998. str. 26-26-x

Podaci o odgovornosti

Mrsić, Mirando ; Batinić, Drago ; Mrsić, Sanja ; Boban, Dubravka ; Nemet, Damir ; Užarević, Branka ; Bogdanić, Vinko ; Aurer, Igor ; Radman, Ivo ; Marković-Glamočak, Mirjana ; Sučić, Mirna ; Sertić, Dubravka ; Pisk, Mirta ; Marušić, Matko ; Labar, Boris

engleski

Unusual marker expression in acute leukaemia is associated with low remission rate

From 1988. to 1998. a total of 40 patients with acute leukaemia (AL) presented with unusual blast immunophenotype. There were 12 females (30%) and 28 males (70%), aged 20-60 (median 41). The FAB types were ALL (10), ALL-L1 (4), undifferentiated AL (AUL, 18) and AML-M1 (8). The basic panel of reagents run on all patients included CD2, CD5, CD10,CD19, CD13,CD33, Cdw65, HLA-DR and CD34, followed by various second-line linegae-associated reagents. Cytogenetic abnormalities were found in 16 of 40 patients with unusual blast-immunophenotype. Match-pair analysis was conducted according to age, sex, FAB, cytogenetic abnormalities and number of WBC at diagnosis. Two control groups were established: AML (n=51) and ALL (n=26). Remission rate for patients with unusual blast marker expression was 48%, which was in contrast to AML (74%) and ALL (68%) (p<0.02). Median remission duration for AL with unusual blast immunophenotype was 6 months (3-15), for AML 18 months (3-42) and for ALL 16 months (3-38) (p<0.02). Probability of relapse was 75% for unusual AL, 42% for AML and 52% for ALL (p<0.03, long rank analysis). However, the probability of leukemia free survival was not different among three studied groups of patients. In conclusion, patients who presented with AL with unusual blast-immunophenotype had significantly lower remission rate and higher relapse rate.

mixed leukemia; immunophenotype; prognosis

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

26-26-x.

1998.

objavljeno

Podaci o matičnoj publikaciji

V. seminar New Trends in the Treatment of Acute Leukemia

Mrsić, Mirando ; Labar, Boris

Zagreb: University Hospital Rebro Zagreb and European School of Oncology

Podaci o skupu

V. seminar New Trends in the Treatment of Acute Leukemia

poster

06.09.1998-09.09.1998

Dubrovnik, Hrvatska

Povezanost rada

Kliničke medicinske znanosti